Scopus BioPharma (SCPS) Competitors $0.0003 0.00 (0.00%) As of 04/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock SCPS vs. HEPA, SMFL, EVLO, CMRA, GNCAQ, GNCA, ARDS, STAB, AMPE, and EFTRShould you be buying Scopus BioPharma stock or one of its competitors? The main competitors of Scopus BioPharma include Hepion Pharmaceuticals (HEPA), Smart for Life (SMFL), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry. Scopus BioPharma vs. Hepion Pharmaceuticals Smart for Life Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma Ampio Pharmaceuticals eFFECTOR Therapeutics Hepion Pharmaceuticals (NASDAQ:HEPA) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations. Does the MarketBeat Community favor HEPA or SCPS? Hepion Pharmaceuticals received 19 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 67.74% of users gave Hepion Pharmaceuticals an outperform vote. CompanyUnderperformOutperformHepion PharmaceuticalsOutperform Votes2167.74% Underperform Votes1032.26% Scopus BioPharmaOutperform Votes2100.00% Underperform VotesNo Votes Do institutionals and insiders believe in HEPA or SCPS? 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 4.7% of Hepion Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer HEPA or SCPS? In the previous week, Hepion Pharmaceuticals had 2 more articles in the media than Scopus BioPharma. MarketBeat recorded 2 mentions for Hepion Pharmaceuticals and 0 mentions for Scopus BioPharma. Scopus BioPharma's average media sentiment score of 0.00 beat Hepion Pharmaceuticals' score of -0.13 indicating that Scopus BioPharma is being referred to more favorably in the news media. Company Overall Sentiment Hepion Pharmaceuticals Neutral Scopus BioPharma Neutral Is HEPA or SCPS more profitable? Scopus BioPharma's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Hepion PharmaceuticalsN/A -812.56% -207.31% Scopus BioPharma N/A N/A N/A Which has stronger valuation and earnings, HEPA or SCPS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHepion PharmaceuticalsN/AN/A-$48.93M-$219.000.00Scopus BioPharmaN/AN/A-$11.61MN/AN/A Which has more volatility & risk, HEPA or SCPS? Hepion Pharmaceuticals has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.27, meaning that its stock price is 127% less volatile than the S&P 500. SummaryScopus BioPharma beats Hepion Pharmaceuticals on 6 of the 10 factors compared between the two stocks. Get Scopus BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCPS vs. The Competition Export to ExcelMetricScopus BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13,000.00$6.44B$5.30B$7.34BDividend YieldN/A3.21%5.45%4.30%P/E RatioN/A6.8921.8617.80Price / SalesN/A230.51380.6697.70Price / CashN/A65.6738.2634.64Price / BookN/A5.936.453.98Net Income-$11.61M$142.99M$3.22B$247.81M1 Month PerformanceN/A-13.57%-9.74%-7.85%1 Year PerformanceN/A-8.90%11.49%1.59% Scopus BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13,000.00N/A0.009HEPAHepion Pharmaceuticals0.3146 of 5 stars$0.37-3.9%N/A-99.7%$51,000.00N/A-0.0820Short Interest ↑News CoverageGap DownSMFLSmart for LifeN/A$0.00-27.8%N/A-100.0%$18,000.00$11.11M0.00110Gap DownEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9,000.00N/A0.00120Options VolumeNews CoverageCMRAComera Life SciencesN/A$0.00flatN/AN/A$6,000.00$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00N/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastNews CoverageARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$5,000.00$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5,000.00N/A0.0020AMPEAmpio PharmaceuticalsN/A$0.00flatN/A-99.1%$2,000.00N/A0.0020Analyst ForecastNews CoverageEFTReFFECTOR TherapeuticsN/A$0.00flatN/A-100.0%$1,000.00$3.55M0.0010 Related Companies and Tools Related Companies Hepion Pharmaceuticals Competitors Smart for Life Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors Ampio Pharmaceuticals Competitors eFFECTOR Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCPS) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scopus BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scopus BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SCPS Stock Free SCPS Stock Alerts